Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas

详细信息    查看全文

• 作者：Victoria K Hill (36)
  Thoraia Shinawi (36)
  Christopher J Ricketts (36)
  Dietmar Krex (37)
  Gabriele Schackert (37)
  Julien Bauer (38)
  Wenbin Wei (39)
  Garth Cruickshank (40)
  Eamonn R Maher (36)
  Farida Latif (36)
  
  36. Centre for Rare Diseases and Personalised Medicine and Department of Medical & Molecular Genetics ; School of Clinical and Experimental Medicine ; University of Birmingham College of Medical and Dental Sciences ; Edgbaston ; Birmingham ; UK
  37. Department of Neurosurgery ; University Hospital Carl Gustav Carus Dresden ; Technical University of Dresden ; Dresden ; Germany
  38. Department of Pathology ; University of Cambridge ; Tennis Court Road ; Cambridge ; CB2 1QP ; UK
  39. School of Cancer Sciences ; University of Birmingham ; Birmingham ; UK
  40. Department of Neurosurgery ; University of Birmingham and Queen Elizabeth Hospital Birmingham ; Birmingham ; UK
  
• 关键词：Primary and secondary glioblastoma (pGBM ; sGBM) ; HumanMethylation450 ; Methylation ; IDH1 ; CIMP
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,258 KB
• 参考文献：1. Tortosa, A, Vinolas, N, Villa, S, Verger, E, Gil, JM, Brell, M, Caral, L, Pujol, T, Acebes, JJ, Ribalta, T, Ferrer, I, Graus, F (2003) Prognostic implication of clinical, radiologic, and patholofic features in patients with anaplastic gliomas. Cancer 15: pp. 1063-1071 CrossRef
  2. Kaye, AH, Walker, DG (2000) Low grade astrocytomas: controversies in management. J Clin Neurosci 7: pp. 475-483 CrossRef
  3. Ohgaki, H, Kleihues, P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19: pp. 764-772 CrossRef
  4. Guo, C, Pirozzi, CJ, Lopez, GY, Yan, H (2011) Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol 24: pp. 648-652 CrossRef
  5. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P, Mankoo, P, Carter, H, Siu, IM, Gallia, GL, Olivi, A, McLendon, R, Rasheed, BA, Keir, S, Nikolskaya, T, Nikolsky, Y, Busam, DA, Tekleab, H, Diaz, LA, Hartigan, J, Smith, DR, Strausberg, RL, Marie, SK, Shinjo, SM, Yan, H, Riggins, GJ, Bigner, DD, Karchin, R, Papadopoulos, N, Parmigiani, G (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: pp. 1807-1812 CrossRef
  6. Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W, Kos, I, Batinic-Haberle, I, Jones, S, Riggins, GJ, Friedman, H, Friedman, A, Reardon, D, Herndon, J, Kinzler, KW, Velculescu, VE, Vogelstein, B, Bigner, DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: pp. 765-773 CrossRef
  7. Jiao, Y, Killela, PJ, Reitman, ZJ, Rasheed, AB, Heaphy, CM, de Wilde, RF, Rodriguez, FJ, Rosemberg, S, Oba-Shinjo, SM, Nagahashi Marie, SK, Bettegowda, C, Agrawal, N, Lipp, E, Pirozzi, C, Lopez, G, He, Y, Friedman, H, Friedman, AH, Riggins, GJ, Holdhoff, M, Burger, P, McLendon, R, Bigner, DD, Vogelstein, B, Meeker, AK, Kinzler, KW, Papadopoulos, N, Diaz, LA, Yan, H (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3: pp. 709-722
  8. Juratli, TA, Kirsch, M, Robel, K, Soucek, S, Geiger, K, von Kummer, R, Schackert, G, Krex, D (2012) IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 108: pp. 403-410 CrossRef
  9. Martinez, R, Esteller, M (2010) The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39: pp. 40-46 CrossRef
  10. Noushmehr, H, Weisenberger, DJ, Diefes, K, Phillips, HS, Pujara, K, Berman, BP, Pan, F, Pelloski, CE, Sulman, EP, Bhat, KP, Verhaak, RG, Hoadley, KA, Hayes, DN, Perou, CM, Schmidt, HK, Ding, L, Wilson, RK, Van Den Berg, D, Shen, H, Bengtsson, H, Neuvial, P, Cope, LM, Buckley, J, Herman, JG, Baylin, SB, Laird, PW, Aldape, K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: pp. 510-522 CrossRef
  11. Wu, X, Rauch, TA, Zhong, X, Bennett, WP, Latif, F, Krex, D, Pfeifer, GP (2010) CpG island hypermethylation in human astrocytomas. Cancer Res 70: pp. 2718-2727 CrossRef
  12. Esteller, M, Garcia-Foncillas, J, Andion, E, Goodman, SN, Hidalgo, OF, Vanaclocha, V, Baylin, SB, Herman, JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: pp. 1350-1354 CrossRef
  13. Weller, M, Stupp, R, Reifenberger, G, Brandes, AA, van den Bent, MJ, Wick, W, Hegi, ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 6: pp. 39-51 CrossRef
  14. Dang, L, White, DW, Gross, S, Bennett, BD, Bittinger, MA, Driggers, EM, Fantin, VR, Jang, HG, Jin, S, Keenan, MC, Marks, KM, Prins, RM, Ward, PS, Yen, KE, Liau, LM, Rabinowitz, JD, Cantley, LC, Thompson, CB, Vander Heiden, MG, Su, SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: pp. 739-744 CrossRef
  15. Turcan, S, Rohle, D, Goenka, A, Walsh, LA, Fang, F, Yilmaz, E, Campos, C, Fabius, AW, Lu, C, Ward, PS, Thompson, CB, Kaufman, A, Guryanova, O, Levine, R, Heguy, A, Viale, A, Morris, LG, Huse, JT, Mellinghoff, IK, Chan, TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: pp. 479-483 CrossRef
  16. Hill, VK, Underhill-Day, N, Krex, D, Robel, K, Sangan, CB, Summersgill, HR, Morris, M, Gentle, D, Chalmers, AD, Maher, ER, Latif, F (2011) Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 30: pp. 978-989 CrossRef
  17. Du, P, Kibbe, WA, Lin, SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: pp. 1547-1548 CrossRef
  18. Edgar, R, Domrachev, M, Lash, AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: pp. 207-210 CrossRef
  19. Hartmann, C, Meyer, J, Balss, J, Capper, D, Mueller, W, Christians, A, Felsberg, J, Wolter, M, Mawrin, C, Wick, W, Weller, M, Herold-Mende, C, Unterberg, A, Jeuken, JW, Wesseling, P, Reifenberger, G, von Deimling, A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differ- entiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: pp. 469-474 CrossRef
  20. Christensen, BC, Smith, AA, Zheng, S, Koestler, DC, Houseman, EA, Marsit, CJ, Wiemels, JL, Nelson, HH, Karagas, MR, Wrensch, MR, Kelsey, KT, Wiencke, JK (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103: pp. 143-153 CrossRef
  21. Moniz, S, Martinho, O, Pinto, F, Sousa, B, Loureiro, C, Oliveira, MJ, Moita, LF, Honavar, M, Pinheiro, C, Pires, M, Lopes, JM, Jones, C, Costello, JF, Paredes, J, Reis, RM, Jordan, P (2013) Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet 22: pp. 84-95 CrossRef
  22. Sandoval, J, Heyn, H, Moran, S, Serra-Musach, J, Pujana, MA, Bibikova, M, Esteller, M (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6: pp. 692-702 CrossRef
  23. Gravendeel, LA, Kloosterhof, NK, Bralten, LBC, van Marion, R, Dubbink, HJ, Dinjens, W, Bleeker, FE, Hoogenraad, CC, Michiels, E, Kros, JM, van den Bent, M, Smitt, PA, French, PJ (2010) Segregation of Non-p.R132H Mutations in IDH1 in Distinct Molecular Subtypes of Glioma. Hum Mutat 31: pp. E1186-E1199 CrossRef
  24. van den Bent, MJ, Dubbink, HJ, Marie, Y, Brandes, AA, Taphoorn, MJ, Wesseling, P, Frenay, M, Tijssen, CC, Lacombe, D, Idbaih, A, van Marion, R, Kros, JM, Dinjens, WN, Gorlia, T, Sanson, M (2010) IDH1 and IDH2 mutations Are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16: pp. 1597-1604 CrossRef
  25. Borodovsky, A, Salmasi, V, Turcan, S, Fabius, AW, Baia, GS, Eberhart, CG, Weingart, JD, Gallia, GL, Baylin, SB, Chan, TA, Riggins, GJ (2013) 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 4: pp. 1737-1747
  26. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/506/prepub
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Grade IV glioblastomas exist in two forms, primary (de novo) glioblastomas (pGBM) that arise without precursor lesions, and the less common secondary glioblastomas (sGBM) which develop from earlier lower grade lesions. Genetic heterogeneity between pGBM and sGBM has been documented as have differences in the methylation of individual genes. A hypermethylator phenotype in grade IV GBMs is now well documented however there has been little comparison between global methylation profiles of pGBM and sGBM samples or of methylation profiles between paired early and late sGBM samples. Methods We performed genome-wide methylation profiling of 20 matched pairs of early and late gliomas using the Infinium HumanMethylation450 BeadChips to assess methylation at >485,000 cytosine positions within the human genome. Results Clustering of our data demonstrated a frequent hypermethylator phenotype that associated with IDH1 mutation in sGBM tumors. In 80% of cases, the hypermethylator status was retained in both the early and late tumor of the same patient, indicating limited alterations to genome-wide methylation during progression and that the CIMP phenotype is an early event. Analysis of hypermethylated loci identified 218 genes frequently methylated across grade II, III and IV tumors indicating a possible role in sGBM tumorigenesis. Comparison of our sGBM data with TCGA pGBM data indicate that IDH1 mutated GBM samples have very similar hypermethylator phenotypes, however the methylation profiles of the majority of samples with WT IDH1 that do not demonstrate a hypermethylator phenotype cluster separately from sGBM samples, indicating underlying differences in methylation profiles. We also identified 180 genes that were methylated only in sGBM. Further analysis of these genes may lead to a better understanding of the pathology of sGBM vs pGBM. Conclusion This is the first study to have documented genome-wide methylation changes within paired early/late astrocytic gliomas on such a large CpG probe set, revealing a number of genes that maybe relevant to secondary gliomagenesis.